Colgate-Palmolive (NYSE:CL) Shares Bought by Canandaigua National Bank & Trust Co.

Canandaigua National Bank & Trust Co. grew its stake in shares of Colgate-Palmolive (NYSE:CL) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,122 shares of the company’s stock after purchasing an additional 211 shares during the quarter. Canandaigua National Bank & Trust Co.’s holdings in Colgate-Palmolive were worth $1,258,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in Colgate-Palmolive by 27.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 41,067,130 shares of the company’s stock valued at $3,698,096,000 after purchasing an additional 8,933,912 shares during the period. Swedbank AB purchased a new stake in shares of Colgate-Palmolive in the first quarter valued at about $286,370,000. Acadian Asset Management LLC raised its holdings in shares of Colgate-Palmolive by 108.4% in the second quarter. Acadian Asset Management LLC now owns 5,682,280 shares of the company’s stock valued at $551,367,000 after buying an additional 2,955,442 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Colgate-Palmolive by 40.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,969,498 shares of the company’s stock valued at $870,400,000 after buying an additional 2,593,313 shares during the last quarter. Finally, Confluence Investment Management LLC purchased a new stake in shares of Colgate-Palmolive in the first quarter valued at about $130,622,000. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Trading Down 0.9 %

NYSE:CL traded down $0.93 during trading hours on Friday, reaching $99.04. 6,030,553 shares of the company were exchanged, compared to its average volume of 4,348,780. The company has a debt-to-equity ratio of 16.90, a current ratio of 1.06 and a quick ratio of 0.70. The firm has a market cap of $81.26 billion, a price-to-earnings ratio of 31.34, a PEG ratio of 3.62 and a beta of 0.40. Colgate-Palmolive has a 52-week low of $67.62 and a 52-week high of $109.30. The stock has a 50 day simple moving average of $103.65 and a 200 day simple moving average of $96.76.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, July 26th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.04. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $5 billion. Colgate-Palmolive had a net margin of 14.21% and a return on equity of 470.19%. The business’s revenue was up 4.9% on a year-over-year basis. During the same period last year, the business earned $0.77 EPS. As a group, analysts predict that Colgate-Palmolive will post 3.57 EPS for the current year.

Colgate-Palmolive Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Friday, October 18th will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.02%. The ex-dividend date is Friday, October 18th. Colgate-Palmolive’s dividend payout ratio is currently 63.29%.

Insiders Place Their Bets

In other Colgate-Palmolive news, Director Martina Hundmejean sold 2,313 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $103.86, for a total transaction of $240,228.18. Following the completion of the transaction, the director now directly owns 11,755 shares of the company’s stock, valued at $1,220,874.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Gregory Malcolm sold 10,533 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $103.10, for a total value of $1,085,952.30. Following the transaction, the executive vice president now directly owns 10,377 shares in the company, valued at approximately $1,069,868.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Martina Hundmejean sold 2,313 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $103.86, for a total transaction of $240,228.18. Following the completion of the transaction, the director now owns 11,755 shares in the company, valued at approximately $1,220,874.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,490 shares of company stock valued at $4,486,063 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

CL has been the subject of a number of research reports. Wells Fargo & Company cut shares of Colgate-Palmolive from an “equal weight” rating to an “underweight” rating and set a $100.00 target price for the company. in a report on Monday, September 16th. Citigroup upped their target price on shares of Colgate-Palmolive from $103.00 to $112.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. UBS Group upped their target price on shares of Colgate-Palmolive from $119.00 to $122.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Sanford C. Bernstein upped their target price on shares of Colgate-Palmolive from $100.00 to $103.00 and gave the stock a “market perform” rating in a research report on Tuesday, July 30th. Finally, Barclays increased their price target on shares of Colgate-Palmolive from $91.00 to $96.00 and gave the company an “equal weight” rating in a research report on Monday, July 29th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Colgate-Palmolive currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.74.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.